Business Description
Aspira Womens Health Inc
NAICS : 334516
SIC : 3841
12117 Bee Caves Road, Suite 100, Building III, Austin, TX, USA, 78738
Description
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.1 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -17.24 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.5 | |||||
| 3-Year EBITDA Growth Rate | -24 | |||||
| 3-Year EPS without NRI Growth Rate | -20.5 | |||||
| 3-Year FCF Growth Rate | -22.5 | |||||
| 3-Year Book Growth Rate | 41.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.3 | |||||
| 9-Day RSI | 56.92 | |||||
| 14-Day RSI | 57.34 | |||||
| 6-1 Month Momentum % | -15.13 | |||||
| 12-1 Month Momentum % | -76.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.85 | |||||
| Quick Ratio | 4.82 | |||||
| Cash Ratio | 4.37 | |||||
| Days Inventory | 12.95 | |||||
| Days Sales Outstanding | 53.58 | |||||
| Days Payable | 134.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.44 | |||||
| Operating Margin % | -498.77 | |||||
| Net Margin % | -485.64 | |||||
| ROE % | -92.33 | |||||
| ROA % | -73.52 | |||||
| ROIC % | -2118.3 | |||||
| ROC (Joel Greenblatt) % | -4156.15 | |||||
| ROCE % | -87.37 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.61 | |||||
| PB Ratio | 4.9 | |||||
| Price-to-Tangible-Book | 5 | |||||
| EV-to-EBIT | -2.33 | |||||
| EV-to-EBITDA | -2.34 | |||||
| EV-to-Revenue | 11.59 | |||||
| EV-to-FCF | -2.64 | |||||
| Price-to-Median-PS-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 5.39 | |||||
| Price-to-Net-Cash | 6.06 | |||||
| Earnings Yield (Greenblatt) % | -42.97 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:AWH
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.209 | ||
| EPS (TTM) ($) | -0.31 | ||
| Beta | 2.23 | ||
| Volatility % | 69.24 | ||
| 14-Day RSI | 57.34 | ||
| 14-Day ATR ($) | 0.116662 | ||
| 20-Day SMA ($) | 0.912675 | ||
| 12-1 Month Momentum % | -76.12 | ||
| 52-Week Range ($) | 0.321 - 4.2499 | ||
| Shares Outstanding (Mil) | 112.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aspira Womens Health Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||